| Species |
Human |
| Protein Construction |
BACE-1 (Thr22-Thr457)
Accession # NP_036236.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to cleave a fluorogenic peptide substrate, McaSEVNLDAEFRK(Dpn)RRNH2. The specific activity is >3.5 pmol/min/µg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
49.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. |
| Synonyms |
Beta-secretase 1; ASP2; Asp 2; BACE1; BACE; FLJ90568; HSPC104; KIAA1149; Memapsin-2; BACE-1; EC 3.4.23; EC 3.4.23.46;β-secretase 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
